分组1 - Concentra Group reported quarterly earnings of $0.39 per share, exceeding the Zacks Consensus Estimate of $0.37 per share, and showing an increase from $0.37 per share a year ago, resulting in an earnings surprise of +5.41% [1] - The company achieved revenues of $572.8 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.31%, and up from $489.64 million year-over-year [2] - Concentra has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed the market, losing about 3.2% since the beginning of the year, while the S&P 500 gained 15.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.25 on revenues of $532.44 million, and for the current fiscal year, it is $1.32 on revenues of $2.15 billion [7] - The Medical Services industry, to which Concentra belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Insights - Farmer Brothers reported a quarterly loss of $0.19 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, marking an earnings surprise of -111.11% [1] - The company's revenues for the quarter ended September 2025 were $81.6 million, missing the Zacks Consensus Estimate by 4.34% and down from $85.07 million a year ago [2] - Farmer Brothers has underperformed the market, with shares down about 2.2% year-to-date compared to the S&P 500's gain of 15.6% [3] Financial Performance - Over the last four quarters, Farmer Brothers has surpassed consensus EPS estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $91.5 million, and for the current fiscal year, it is -$0.44 on revenues of $354.5 million [7] Industry Context - The Food - Natural Foods Products industry, to which Farmer Brothers belongs, is currently in the bottom 8% of over 250 Zacks industries, indicating a challenging environment [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Farmer Brothers' stock performance [5][6]

Core Insights - Alector reported a quarterly loss of $0.34 per share, better than the Zacks Consensus Estimate of a loss of $0.42, marking an earnings surprise of +19.05% [1] - The company generated revenues of $3.26 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 24.19%, but down from $15.34 million year-over-year [2] - Alector's stock has underperformed, losing approximately 33.6% since the beginning of the year, while the S&P 500 has gained 15.6% [3] Financial Performance - Over the last four quarters, Alector has surpassed consensus EPS estimates four times and topped revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $3 million, and for the current fiscal year, it is -$1.57 on revenues of $17.15 million [7] Industry Context - Alector operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 41% of over 250 Zacks industries [8] - The industry’s performance can significantly impact Alector's stock performance, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] Future Outlook - The sustainability of Alector's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The estimate revisions trend for Alector was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6]

Core Insights - Willdan Group (WLDN) reported quarterly earnings of $1.21 per share, exceeding the Zacks Consensus Estimate of $0.81 per share, and showing an increase from $0.73 per share a year ago, resulting in an earnings surprise of +49.38% [1] - The company achieved revenues of $94.97 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 11.53%, although this is a decline from year-ago revenues of $158.25 million [2] - Willdan shares have increased approximately 147.1% year-to-date, significantly outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook, which includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $0.86 on revenues of $82.6 million, and for the current fiscal year, it is $3.60 on revenues of $348.05 million [7] Industry Context - The Business - Services industry, to which Willdan belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Willdan's stock may also be influenced by the overall outlook for the industry, as empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]

Core Insights - ClearPoint Neuro, Inc. reported a quarterly loss of $0.21 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.20, marking a year-over-year increase from a loss of $0.18 per share [1] - The company generated revenues of $8.86 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 10.5%, but showing an increase from $8.12 million in the same quarter last year [2] - ClearPoint Neuro's stock has increased by approximately 10.4% since the beginning of the year, underperforming compared to the S&P 500's gain of 15.6% [3] Earnings Outlook - The earnings outlook for ClearPoint Neuro is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.19 on revenues of $10.7 million, and for the current fiscal year at -$0.81 on revenues of $38.3 million [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which ClearPoint Neuro belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

分组1 - Janux Therapeutics reported a quarterly loss of $0.39 per share, better than the Zacks Consensus Estimate of a loss of $0.60, and improved from a loss of $0.51 per share a year ago, resulting in an earnings surprise of +35.00% [1] - The company posted revenues of $10 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 28.01%, compared to revenues of $0.44 million in the same quarter last year [2] - Janux Therapeutics shares have declined approximately 48.6% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] 分组2 - The earnings outlook for Janux Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.74 on revenues of $1.25 million, and -$2.37 on revenues of $8.13 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Janux Therapeutics belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Insights - TruBridge (TBRG) reported quarterly earnings of $0.88 per share, exceeding the Zacks Consensus Estimate of $0.4 per share, and showing a significant improvement from a loss of $0.21 per share a year ago, resulting in an earnings surprise of +120.00% [1] - The company achieved revenues of $86.11 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.32% and reflecting a year-over-year increase from $83.83 million [2] - TruBridge has outperformed consensus revenue estimates three times over the last four quarters [2] Earnings Outlook - The sustainability of TruBridge's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.46 on revenues of $88.61 million, and for the current fiscal year, it is $1.76 on revenues of $346.54 million [7] Industry Context - The Medical Info Systems industry, to which TruBridge belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - JFrog Ltd. reported quarterly earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.16 per share, and showing an increase from $0.15 per share a year ago, resulting in an earnings surprise of +37.50% [1] - The company achieved revenues of $136.91 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 6.63% and up from $109.06 million year-over-year [2] - JFrog shares have increased approximately 56.8% year-to-date, significantly outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The future performance of JFrog's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $131.57 million, and for the current fiscal year, it is $0.70 on revenues of $509.48 million [7] Industry Context - The Internet - Software industry, to which JFrog belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8]

分组1 - 10x Genomics reported a quarterly loss of $0.22 per share, better than the Zacks Consensus Estimate of a loss of $0.27, and an improvement from a loss of $0.30 per share a year ago, resulting in an earnings surprise of +18.52% [1] - The company achieved revenues of $149 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.64%, although this represents a decline from year-ago revenues of $151.65 million [2] - Over the last four quarters, 10x Genomics has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] 分组2 - The stock has underperformed the market, losing about 6.1% since the beginning of the year, while the S&P 500 has gained 15.6% [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates of -$0.23 for the coming quarter and -$0.52 for the current fiscal year, alongside revenues of $151.08 million and $620.66 million respectively [7] - The Medical Info Systems industry, to which 10x Genomics belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable industry outlook [8]

Core Viewpoint - Nerdy Inc. reported a quarterly loss of $0.1 per share, which was better than the Zacks Consensus Estimate of a loss of $0.16, indicating a positive earnings surprise of +37.50% [1] - The company’s revenues for the quarter were $37.02 million, missing the Zacks Consensus Estimate by 5.58% and down from $37.53 million a year ago [2] Financial Performance - Over the last four quarters, Nerdy has surpassed consensus EPS estimates four times and topped revenue estimates twice [2] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $59.31 million, and for the current fiscal year, it is -$0.34 on revenues of $191.39 million [7] Stock Performance - Nerdy shares have declined approximately 40.1% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Schools industry, to which Nerdy belongs, is currently ranked in the bottom 31% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of Nerdy may also be influenced by the upcoming earnings report of KinderCare Learning Companies, Inc., another player in the same industry [9]